

# SYNTHESIS AND ANTI-PROLIFERATIVE ACTIVITY OF NOVEL AMIDINO-SUBSTITUTED ARYL-BISBENZOTHAZOLES

## Sinteza i antiproliferativna aktivnost novih amidino-supstituiranih arilnih bisbenzotiazola

Lucija Ptiček,<sup>1</sup> Marija Mudrešić,<sup>1</sup> Petra Grbčić,<sup>2</sup> Sandra Kraljević Pavelić,<sup>2</sup> Livio Racané<sup>1</sup>

<sup>1</sup> Department of Applied Chemistry, Faculty of Textile Technology, University of Zagreb, Prilaz baruna Filipovića 28a, 10000 Zagreb, Croatia

<sup>2</sup> Department of Biotechnology, Centre for high-throughput technologies, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, Croatia

### INTRODUCTION

2-Arylbenzothiazole derivatives are of considerable interest due to their diverse pharmaceutical properties and have emerged as a privileged scaffold in drug discovery bearing remarkable activity profiles in non-invasive diagnosis of Alzheimer's disease and antitumour effects [1]. Strong anti-proliferative effects on some tumour cell lines were previously shown for 2-arylbenzothiazole derivatives [1], isomeric imidazolyl-substituted phenylene-bisbenzothiazole [2] and imidazolyl-substituted phenyl- and naphthyl-benzothiazoles [3]. These findings have led us to further investigate this class of compounds by introducing different types of amidinic substituents into the structure with the aim of improving activity and selectivity on different human tumour cell lines.

### RESULTS AND DISCUSSION

We found new synthetic method for preparation of isomeric amidino-substituted derivatives of bisbenzothiazolyl-phenylenes and naphthalenes (scheme 1). Screening of anti-proliferative activity was performed on four human tumour cell lines *in vitro*: CFPAC-1 (ductal pancreatic adenocarcinoma), SW620 (metastatic, colorectal adenocarcinoma), HepG2 (hepatocellular carcinoma) and HeLa (cervical carcinoma). Obtained results are presented in Table 1. *In vitro* anti-proliferative screening of novel diamidino-bisbenzothiazolyl derivatives 5a-5i revealed strong activity on tested cell lines, depending on the type of amidinic substituent as well as positions of benzothiazolyl moieties.




Table 1. *In vitro* anti-proliferative activity of amidino-substituted derivatives 5a-5i on four different tumour cell lines

Compound	IC <sub>50</sub> <sup>a</sup> / mM			
	Tested cell lines			
	SW620	HepG2	CFPAC-1	HeLa
5a	8.20±1.12	>100	>100	4.38±0.69
5b	0.08±0.02	0.16±0.09	0.09±0.01	0.07±0.09
5c	0.40±0.12	5.95±0.64	6.41±1.36	0.74±0.51
5d	7.13±1.65	5.01±0.96	9.09±1.47	1.31±0.96
5e	0.09±0.01	3.16±0.68	5.90±0.09	0.65±1.41
5f	0.26±0.06	0.3±0.09	2.10±0.84	0.41±0.90
5g	0.08±0.74	0.94±0.35	42.46±8.86	0.71±0.09
5h	0.09±0.85	1.53±0.29	5.92±1.88	1.34±0.76
5i	0.22±0.11	0.39±0.24	1.08±0.15	0.68±0.43

<sup>a</sup>Compound concentration required to inhibit tumor cell proliferation by 50%

### REFERENCES

- [1] A. A. Weekes and A. D. Westwell, *Current Medicinal Chemistry* 16 (2009) 2430-2440.
- [2] L. Racané, S. Kraljević Pavelić, R. Nhili, S. Depauw, C. Paul-Constant, I. Ratkaj, M.-H. David-Cordonnier, K. Pavelić, V. Tralić-Kulenović and G. Karminski-Zamola, *European Journal of Medicinal Chemistry* 63 (2013) 882-891.
- [3] L. Racané, L. Ptiček, M. Sedić, P. Grbčić, S. Kraljević Pavelić, B. Bertoša, I. Sović and G. Karminski-Zamola, *Molecular Diversity* 22 (2018) 723-741.